# Study of Influenza Vaccines Containing an Additional H3 Antigen in Healthy Adult Participants 18 to 49 Years of Age and 60 Years of Age and Older

> **NCT06507553** · PHASE1 · COMPLETED · sponsor: **Sanofi Pasteur, a Sanofi Company** · enrollment: 400 (actual)

## Conditions studied

- Influenza
- Healthy Volunteers

## Interventions

- **BIOLOGICAL:** Trivalent-Darwin influenza vaccine
- **BIOLOGICAL:** Augment-Tasmania influenza vaccine
- **BIOLOGICAL:** TIV-2X Darwin influenza vaccine
- **BIOLOGICAL:** Trivalent-Tasmania influenza vaccine

## Key facts

- **NCT ID:** NCT06507553
- **Lead sponsor:** Sanofi Pasteur, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-12
- **Primary completion:** 2025-03-04
- **Final completion:** 2025-03-04
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2025-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06507553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06507553, "Study of Influenza Vaccines Containing an Additional H3 Antigen in Healthy Adult Participants 18 to 49 Years of Age and 60 Years of Age and Older". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06507553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*